search
Back to results

Whole-body Vibration in Children With Neurofibromatosis Type 1

Primary Purpose

Neurofibromatosis Type 1, Muscle Weakness

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Whole-body vibration
Muscle strengthening exercises
Sponsored by
Manchester University NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neurofibromatosis Type 1 focused on measuring Neurofibromatosis Type 1, Whole-body vibration, Muscle weakness

Eligibility Criteria

6 Years - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Neurofibromatosis Type 1 (confirmed by NIH consensus criteria)
  • Grip force less than -1 SDS according to age- and gender-matched normative data

Exclusion Criteria:

  • Focal skeletal abnormalities (pseudoarthrosis, kyphoscoliosis likely to require surgery, known spondylolisthesis)
  • Significant autistic spectrum disorder or learning difficulties (neurodevelopmental age less than 6 years)
  • Inability to adequately weight-bear or balance on vibrating platform
  • Lower limb plexiform causing limb length discrepancy
  • Contraindications to use of whole-body vibration device (acute thrombosis, implants in activated regions of the body, acute inflammation of the locomotor system, herniae, propensity to fragility fractures or fracture within the past 3 months, history of renal calculi, epilepsy)

Sites / Locations

  • Manchester University Hospitals NHS Foundation Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Exercises

Whole-body vibration + exercises

Arm Description

Daily muscle-strengthening exercises

Home-based whole-body vibration therapy plus daily muscle-strengthening exercises

Outcomes

Primary Outcome Measures

Change in peak power per kilogram on single two-legged jump using Leonardo Mechanography Ground Reaction Force Plate
Change from baseline to 6 months of peak power per kilogram of single two-legged jump using Leonardo Mechanography Ground Reaction Force Plate. Power will be measured in watts.

Secondary Outcome Measures

6 minute walk test
Distance in metres walked during 6 minutes
Accelerometer (duration)
Duration of activity in minutes over 7 days using accelerometer
Accelerometer (intensity)
Intensity of activity (accelerometer counts per minute) over 7 days using accelerometer
PedsQL Multi-dimensional Fatigue Scale
Total score from age-appropriate validated questionnaire that asks for perceived fatigue within the domains of 'General', 'Sleep/Rest' and 'Cognitive'. Each domain consists of 6 questions, with participants/parents rating each question from 0 to 4 (therefore total score can range from 0 to 72). A higher total score indicates greater fatigue (i.e. worse outcome)

Full Information

First Posted
March 20, 2019
Last Updated
March 15, 2021
Sponsor
Manchester University NHS Foundation Trust
Collaborators
Manchester Metropolitan University
search

1. Study Identification

Unique Protocol Identification Number
NCT03888248
Brief Title
Whole-body Vibration in Children With Neurofibromatosis Type 1
Official Title
Whole-body Vibration Training Compared to Muscle-strengthening Exercises Alone in Improving Muscle Function in Children With Neurofibromatosis Type 1
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
July 22, 2019 (Actual)
Primary Completion Date
November 30, 2020 (Actual)
Study Completion Date
November 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Manchester University NHS Foundation Trust
Collaborators
Manchester Metropolitan University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
It is known that children with NF1 can have weak muscles and suffer from tiredness. It is also known that in similar conditions affecting children's muscles, standing on a vibration device for a few minutes each day can strengthen muscles and improve their ability to perform day-to-day activities. The investigators believe this vibrating platform can be used to strengthen the muscles of children with NF1 also, beyond standard exercises, and therefore allow them to perform day-to-day activities better, do more activity and feel less tired. If families are keen to take part in this study, the investigators will first need to check they are suitable for the trial. This will be based on the participant's age (6-16 years), their other medical problems that would affect use of the vibration device or tests to assess how effective it is, and their level of muscle weakness. Once families have agreed to take part, participants will be randomised either to receive a muscle-strengthening exercise session delivered by a physiotherapist that children with weak muscles should continue to perform daily for the next 6 months; or to receive a vibration device to take home and use for a few minutes 5 days a week for 6 months as well as the exercises. All participants will be invited to attend for a variety of activities and tests, just before starting the trial and 6 months later at the end of the trial to see if there is any benefit from the vibration device. The investigators will repeat these tests again 3 months later, to see if any benefits observed remain, even after the device is removed. They will involve jumping, hopping and balancing on a board, gripping a machine as hard and as long as possible, being fitted with a device that measures activity for 7 days, walking as far as possible for 6 minutes, scanning muscles using MRI, completing a tiredness and general well-being questionnaires, and parents completing a questionnaire of the participant's attention and intellect. The jumping will also be performed 3 months into the study, to see if there is any early improvement in this key test. All participants will be given full details of what the trial involves before taking part. As with any other trial, participants and their families are free to stop taking part at any time. Although the investigators do not anticipate any safety issues, if any do arise, the families will be asked to contact the trial team.
Detailed Description
Children with neurofibromatosis type 1 (NF1) have been shown in many studies to have reduced muscle mass, strength and function. This could potentially contribute to the fatigue and low quality of life reported in these children. However, to date interventions to improve muscle mass, strength and function in these children have not been established. Whole body vibration (WBV) has been demonstrated to improve walking speed and distance, muscle mass and strength, spasticity and balance in children with other neuromuscular conditions. In this proposed preliminary matched-pairs interventional trial, the investigators aim to identify whether a home-based WBV therapy programme (9 minutes twice daily for 5 days per week) in addition to standard daily muscle-strengthening exercises improves muscle mass, strength and function over a six month period in children with NF1 aged 6-16 years, compared to daily muscle-strengthening exercises alone. Participants must have evidence of poor muscle strength, with grip force used to assess for this. Key exclusion criteria include significant learning difficulty or autistic spectrum disorder which would create difficulty in use of the WBV device, focal skeletal abnormalities and contraindications to WBV therapy. The primary outcome measure will be dynamic muscle function using mechanography to measure peak power per kilogram on single two-legged jump. Secondary/exploratory outcome measures include the 6-minute walk test (to assess lower limb muscle function and mobility), accelerometer data (as a surrogate marker of type and duration of physical activity), hand-held dynamometry (to assess upper limb grip force and endurance), measures on mechanography other than jumping power (to further assess dynamic muscle function), MRI for muscle cross-sectional area and signal intensity, fatigue and general well-being questionnaires and parental reports of attention and cognition. These measures will be undertaken at baseline, on completion of intervention at 6 months, and again 3 months after to identify whether there is any sustained effect of the intervention following removal. Halfway through the intervention period (3 months), participants will also be invited just to complete the primary outcome of single two-legged jump on ground reaction force plate, as an interim measure. The investigators hypothesise that WBV therapy will result in increased muscle mass and passive muscle strengthening of the lower limbs, which will translate into better muscle function in the lower limbs compared to baseline data and control group. As it is hypothesised that muscle weakness contributes to the fatigue demonstrated in children with NF1, the investigators would expect to see an improvement in their fatigue scores, which, combined with greater muscle strength, will translate into greater physical activity. The investigators hypothesise that WBV may also have an impact on muscle function in the upper limbs through central sensory stimulation and neuronal rewiring. Many children with NF1 have evidence of attention problems, and the investigators hypothesise that this may improve with WBV, again through central neuronal rewiring. The trial will be conducted in compliance with this protocol, Good Clinical Practice (GCP) and applicable regulatory requirements.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neurofibromatosis Type 1, Muscle Weakness
Keywords
Neurofibromatosis Type 1, Whole-body vibration, Muscle weakness

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Exercises
Arm Type
Active Comparator
Arm Description
Daily muscle-strengthening exercises
Arm Title
Whole-body vibration + exercises
Arm Type
Experimental
Arm Description
Home-based whole-body vibration therapy plus daily muscle-strengthening exercises
Intervention Type
Device
Intervention Name(s)
Whole-body vibration
Intervention Description
Home-based whole-body vibration therapy by standing on Galileo Med 15 platform for 9 mins twice a day for 5 days per week
Intervention Type
Other
Intervention Name(s)
Muscle strengthening exercises
Intervention Description
Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist
Primary Outcome Measure Information:
Title
Change in peak power per kilogram on single two-legged jump using Leonardo Mechanography Ground Reaction Force Plate
Description
Change from baseline to 6 months of peak power per kilogram of single two-legged jump using Leonardo Mechanography Ground Reaction Force Plate. Power will be measured in watts.
Time Frame
Baseline, 6 months
Secondary Outcome Measure Information:
Title
6 minute walk test
Description
Distance in metres walked during 6 minutes
Time Frame
Baseline, 6 months, 9 months
Title
Accelerometer (duration)
Description
Duration of activity in minutes over 7 days using accelerometer
Time Frame
Baseline, 6 months, 9 months
Title
Accelerometer (intensity)
Description
Intensity of activity (accelerometer counts per minute) over 7 days using accelerometer
Time Frame
Baseline, 6 months, 9 months
Title
PedsQL Multi-dimensional Fatigue Scale
Description
Total score from age-appropriate validated questionnaire that asks for perceived fatigue within the domains of 'General', 'Sleep/Rest' and 'Cognitive'. Each domain consists of 6 questions, with participants/parents rating each question from 0 to 4 (therefore total score can range from 0 to 72). A higher total score indicates greater fatigue (i.e. worse outcome)
Time Frame
Baseline, 6 months, 9 months
Other Pre-specified Outcome Measures:
Title
Peak force (newtons) per kilogram on multiple one-legged hop using Leonardo Mechanography Ground Reaction Force Plate
Time Frame
Baseline, 6 months, 9 months
Title
Efficiency of single two-legged jump using Leonardo Mechanography Ground Reaction Force Plate
Description
Efficiency is calculated by the Leonardo software by comparing peak force and peak power, and is an indicator of movement velocity and co-ordination. The software will automatically calculate z-score (based on weight, age and gender), which will be used for analysis
Time Frame
Baseline, 6 months, 9 months
Title
Balance tasks
Description
Most complex balance task that can be performed for 10 seconds will be recorded (increasing in complexity from Romberg stance, to semi-tandem stance, to tandem stance, to balancing on one foot). This will be performed on Leonardo Mechanography Ground Reaction Force Plate
Time Frame
Baseline, 6 months, 9 months
Title
Path length using Leonardo Mechanography Ground Reaction Force Plate
Description
Path length in centimetres of the completed balance tasks
Time Frame
Baseline, 6 months, 9 months
Title
Ellipse area using Leonardo Mechanography Ground Reaction Force Plate
Description
Ellipse area in centimetres squared of the completed tasks
Time Frame
Baseline, 6 months, 9 months
Title
Maximal hand grip force
Description
Maximal hand grip force (newtons) using hand-held dynamometry
Time Frame
Baseline, 6 months, 9 months
Title
Sustained grip force
Description
Sustained grip force (newtons) over 10 seconds using hand-held dynamometry
Time Frame
Baseline, 6 months, 9 months
Title
Magnetic resonance imaging of right calf muscle
Description
Cross-sectional area in centimetres squared of calf muscles in right leg
Time Frame
Baseline, 6 months, 9 months
Title
Magnetic resonance imaging of right mid-thigh muscle
Description
Cross-sectional area in centimetres squared of mid-thigh muscles in right leg
Time Frame
Baseline, 6 months, 9 months
Title
Magnetic resonance imaging - signal intensity
Description
Average signal intensity of right leg muscle on MRI
Time Frame
Baseline, 6 months, 9 months
Title
Child Outcome Rating Scale
Description
Total score from non-validated visual analog scale of participant's perception of lifestyle and well-being. This will assess participant's perception of 6 domains: 'Mood and emotional well-being', 'Tiredness/fatigue', 'Hobbies/interests/activities', 'School', 'Attention/concentration' and ''Overall'. Each domain is on a 10cm rule, therefore total score can range from 0 to 60. A higher score indicates better well-being (i.e. better outcome).
Time Frame
Baseline, 6 months, 9 months
Title
Conners Parent Rating Scale
Description
Total score on validated questionnaire for parental report of attention deficit hyperactivity disorder (ADHD) symptomatology, within domains of 'Inattention', 'Hyperactivity/impulsivity', 'Learning problems', 'Executive functioning', 'Aggression' and 'Peer relations'. There are 45 questions, each rated on a scale of 0 to 3 (therefore total score can range from 0 to 135). A higher score indicates greater features of ADHD (i.e. worse outcome).
Time Frame
Baseline, 6 months, 9 months
Title
Persistence of changes in primary outcome on withdrawal of intervention
Description
Change from baseline to 9 months (i.e. 3 months after withdrawal of intervention) of peak power (in watts) per kilogram of single two-legged jump using Leonardo Mechanography Ground Reaction Force Plate
Time Frame
Baseline, 9 months
Title
Evidence of early changes in primary outcome
Description
Change from baseline to 3 months (i.e. half way through intervention) of peak power (in watts) per kilogram of single two-legged jump using Leonardo Mechanography Ground Reaction Force Plate
Time Frame
Baseline, 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Neurofibromatosis Type 1 (confirmed by NIH consensus criteria) Grip force less than -1 SDS according to age- and gender-matched normative data Exclusion Criteria: Focal skeletal abnormalities (pseudoarthrosis, kyphoscoliosis likely to require surgery, known spondylolisthesis) Significant autistic spectrum disorder or learning difficulties (neurodevelopmental age less than 6 years) Inability to adequately weight-bear or balance on vibrating platform Lower limb plexiform causing limb length discrepancy Contraindications to use of whole-body vibration device (acute thrombosis, implants in activated regions of the body, acute inflammation of the locomotor system, herniae, propensity to fragility fractures or fracture within the past 3 months, history of renal calculi, epilepsy)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zulf Mughal
Organizational Affiliation
Manchester University NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Manchester University Hospitals NHS Foundation Trust
City
Manchester
ZIP/Postal Code
M13 9WL
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Whole-body Vibration in Children With Neurofibromatosis Type 1

We'll reach out to this number within 24 hrs